| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

LifeVantage Corporation (NASDAQ: LFVN) Q4 Earnings Overview

LifeVantage Corporation (NASDAQ: LFVN) is a health and wellness company known for its focus on nutritional supplements and skincare products. The company operates globally, with significant markets in the Americas, Asia/Pacific, and Europe. LifeVantage competes with other health and wellness companies, striving to maintain its market position through innovative products and strategic growth.

On September 4, 2025, LifeVantage reported its Q4 earnings, revealing an earnings per share (EPS) of $0.14, which fell short of the expected $0.17. Despite this, the company showed a year-over-year improvement, with net income per diluted share rising to $0.15 from $0.10. Adjusted earnings per diluted share also increased to $0.17 from $0.14, indicating some positive financial momentum.

The company's revenue for the fourth quarter was $55.1 million, below the anticipated $57.9 million. However, this still represented a 12.6% increase from the previous year. In the Americas, revenue grew by 14.1%, while Asia/Pacific and Europe saw a 7.6% increase. Excluding foreign currency impacts, the growth in Asia/Pacific and Europe was 1.6%, highlighting regional performance variations.

LifeVantage's financial metrics provide further insight into its market position. The company has a price-to-earnings (P/E) ratio of 15.22 and a price-to-sales ratio of 0.67, indicating how the market values its earnings and revenue. The enterprise value to sales ratio is 0.62, suggesting a slightly lower valuation when accounting for debt and cash.

The company's financial health is supported by a debt-to-equity ratio of 0.36, reflecting moderate debt levels. With a current ratio of 1.66, LifeVantage demonstrates strong liquidity, ensuring it can meet short-term liabilities. The earnings yield of 6.57% offers insight into the earnings generated per dollar invested, showcasing the company's profitability.

Published on: September 5, 2025